Somatic mutations predict an aggressive phenotype in meningioma but do not drive grade progression
EGAS00001006585, EGAD00001009391Cain et al., 2023
Overview
- Modality
- Targeted panel sequencingWES
- Sample count
- 50
- Patient count
- 10
- Institution
- University of Melbourne / Royal Melbourne Hospital
- Corresponding author
- Kate J. Drummond
- Platform
- Illumina NovaSeq 6000 (TruSight Oncology 500); Agilent SureSelect Clinical Research Exome V2 (subset)
- Access type
- controlled
- Tissue preservation
- Not reported
- WHO edition
- Not reported
Cohort detail
- Grade breakdown
- G1: 21 G2: 19 G3: 23
- Sex distribution
- 4 female, 6 male (10 patients)
- Age distribution
- Not reported
- Anatomic location
- Per the publication abstract, among NF2-mutated tumours 94% were non-skull base (the 94% figure applies specifically to the NF2-mutated subset, not the whole cohort); overall per-sample anatomic location is not broken down in the live EGA dataset metadata
- Brain invasion
- Not reported
- Normal/control tissue
- None
Priority attributes
WHO grade breakdown availablePeer-reviewed
Publications
- Cain SA, et al. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression. BMC Cancer, 2023. PMID 36882706 · DOI
Sources
- EGA study pagehttps://ega-archive.org/studies/EGAS00001006585
- EGA dataset pagehttps://ega-archive.org/datasets/EGAD00001009391
- PubMedhttps://pubmed.ncbi.nlm.nih.gov/36882706/
- DOIhttps://doi.org/10.1186/s12885-023-10624-9